ORPH.L Regulatory News (ORPH)

28 June 2018

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Result of AGM

Venn Life Sciences (AIM: VENN), an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device clients, that at the Company's Annual General Meeting held yesterday, all but resolution 6 of the resolutions put to the meeting were duly passed. Resolution 6 was a special resolution requiring 75 per cent. of votes cast to be in favour in order to be passed and sought the approval of shareholders to the dis-application of pre-emption rights to allot and issue new ordinary share for cash, per section 561 of the Companies Act 2006.

Enquiries:

About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

For more information about the Company, please visit: www.vennlifesciences.com